What should clinical AI validation prove?

Clinical AI validation should support the product's intended use and deployment claim. It should make clear the users, patient group, setting, reference standard, performance limits, limitations, safety controls and what the evidence does not prove.

Is clinical AI validation the same as AI clinical safety?

No. Validation asks whether evidence supports the intended claim. AI clinical safety asks how clinical risk is identified, controlled and governed in the health IT workflow. NHS-facing products often need both streams aligned.

Can Dr Chiho Song help with DTAC and DCB 0129 for AI validation?

Yes, for suitable scopes. Dr Chiho Song can help connect validation evidence to DTAC clinical safety evidence, DCB 0129 clinical risk management and Clinical Safety Officer review where the product route is clinically defensible.

Clinical AI validation consultant

Clinical AI evidence that matches
the NHS use case.

Dr Chiho Song helps NHS-facing teams make clinical AI validation evidence defensible: intended use, target users, patient group, reference standard, claim limits, AI clinical safety, DTAC, DCB 0129 and governance after deployment.

Discuss validation evidence → AI clinical safety

ClaimIntended use before metrics

EvidenceValidation matched to context

SafetyGovernance before go-live

Short answer

Who can help validate clinical AI for NHS deployment?

For suitable NHS-facing clinical AI products, Dr Chiho Song can support validation planning and evidence review. The work is not to inflate model performance; it is to make sure the evidence supports the intended use, clinical claim, user, patient group, workflow and safety case.

This is a clinician-led route for teams that need validation evidence to connect with AI clinical safety, DTAC, DCB 0129, medical-device questions and post-go-live governance.

Validation scope

Useful evidence starts with a precise claim.

A validation result is only useful if it is tied to the product's real clinical use. A high metric in the wrong cohort, setting or workflow can be actively misleading.

Intended use

Define what the product supports, who uses it, the patient group, the setting, the decision point and what the AI is not allowed to claim.

Reference standard

Decide what the AI output is being compared against and whether that standard is clinically meaningful for the target pathway.

Cohort fit

Check whether the validation cohort reflects the NHS deployment context closely enough to support the intended claim.

Metric choice

Use metrics that match the clinical consequence of error. Sensitivity, specificity, calibration, workload and subgroup performance may matter differently.

Claim limits

State what the evidence supports and what it does not. This is critical for safe buyer review, clinical safety and responsible product language.

Governance

Plan what triggers evidence refresh after deployment: model change, workflow change, incident signals, new users or a broader intended use.

What Dr Song can help with

Validation evidence that links to deployment decisions.

Claim review intended use, user, setting, patient group and excluded use Evidence plan reference standard, cohort, endpoints, subgroup checks and limitations Safety link how evidence claims connect to AI hazards and DCB 0129 controls DTAC readiness clinical safety and evidence language suitable for NHS review Governance monitoring, change control and evidence refresh after go-live Boundary setting clear public claims without exposing confidential product logic

Related routes

Use the more specific page when the need narrows.

NHS implementation

Need clinical AI validation reviewed?

Send the intended use, target users, patient group, model output, current evidence, target NHS setting and what decision the evidence needs to support.

Book a validation call → Email the details